Artios aims to be the leading independent DDR company with a strong array of new cancer therapies in development. Our cutting-edge DDR programmes have potential applications across a broad range of cancersFind out how
- 12:15 PM May 30thArtios Pharma CEO Niall Martin was featured in InVivo’s piece on “Biotech CEOs: Entrepreneurs who want to translate… https://t.co/jbjSBuNAQE
- 08:08 PM Mar 31stArtios Pharma are currently at the AACR Annual Meeting being held in Atlanta. Drs Niall Martin, Graeme Smith, Harry… https://t.co/fI9Lwutgbi
- 12:44 PM Mar 19thArtios Pharma is in Business Weekly’s Killer 50 companies. https://t.co/FNLF0V169M
- 02:52 PM Mar 13thDr Niall Martin, CEO of Artios Pharma is attending BioCapital in Amsterdam tomorrow, March 14th.
- 11:24 AM Nov 14th@artiospharma a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, wins the 201… https://t.co/uBfQPI8hYO
We have in-licensed lead programmes from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK) and we are working in collaboration with them and other world leaders in DDR to discover and develop exciting new programmes